A clinical case of multiple myeloma complicated by renal amyloidosis

Tatsiana Barysenka; R. B. S. W. M. Pasan M. Kokwewa; M. M. Shalini P. Gawarammana

doi:10.18203/2320-6012.ijrms20253985

Authors

Tatsiana Barysenka Department of Internal Diseases, Grodno State Medical University, Grodno, Belarus
R. B. S. W. M. Pasan M. Kokwewa Department of Internal Diseases, Grodno State Medical University, Grodno, Belarus
M. M. Shalini P. Gawarammana Department of Internal Diseases, Grodno State Medical University, Grodno, Belarus https://orcid.org/0009-0003-5838-369X

DOI:

https://doi.org/10.18203/2320-6012.ijrms20253985

Keywords:

Multiple myeloma, Renal amyloidosis, End-stage chronic kidney disease, Nephrobiopsy, ELISA analysis Beta-2 microglobulin

Abstract

Multiple myeloma is a hematological malignancy effecting multiple organ systems. One of the commonly effected organs are the kidneys leading to renal amyloidosis and nephrotic syndrome. This article describes a clinical case of a patient presenting with end-stage renal failure. It mainly discusses the investigations used to come to a clinical diagnosis of multiple myeloma and renal amyloidosis and the treatment strategies used in managing the patient.

Metrics

Metrics Loading ...

Author Biographies

Tatsiana Barysenka, Department of Internal Diseases, Grodno State Medical University, Grodno, Belarus

Department of Internal Diseases, Grodno State Medical University, Grodno, Belarus

M. M. Shalini P. Gawarammana, Department of Internal Diseases, Grodno State Medical University, Grodno, Belarus

Department of Internal Diseases, Grodno State Medical University, Grodno, Belarus

References

Blommestein HM, van Beurden-Tan CHY, Franken MG, Uyl-de Groot CA, Sonneveld P, Zweegman S. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica. 2019;104(5):1026-35. DOI: https://doi.org/10.3324/haematol.2018.206912

Pasca S, Tomuleasa C, Teodorescu P, Ghiaur G, Dima D, Moisoiu V, et al. KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma. Front Oncol. 2019;9:1137. DOI: https://doi.org/10.3389/fonc.2019.01137

Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016;128(23):2599-606. DOI: https://doi.org/10.1182/blood-2016-09-692954

Lee IH, Kim CY, Kang S, Ahn DJ, Kim MK. Multiple myeloma-associated light chain amyloidosis involving heart, kidneys, and peripheral nerves. A case report. Medicine. 2021;2(8):e0128. DOI: https://doi.org/10.1097/MD9.0000000000000128

Leal G, Ballardin B, Rissete M, Amenábar J, Schussel J. Lingual amyloidosis associated to multiple myeloma: case report. RGO - Revista Gaúcha de Odontologia. 2022;70:e20220029. DOI: https://doi.org/10.1590/1981-86372022002920210002

Gurung R, Li T. Renal Amyloidosis: Presentation, Diagnosis, and Management. Am J Med. 2022;135:S38-43.

Bhuyan N, Chaubey M, Chakravarty J, Pal A. Renal amyloidosis causing nephrotic syndrome: An unusual presentation of light chain myeloma. Nat J Physiol Pharm Pharmacol. 2022;10(4):352-4.

Innocenti S, Bacchi B, Allinovi M, Perfetto F, Antonioli E, Marchionni N, et al. A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis. BMC Nephrol. 2022;23(1):370. DOI: https://doi.org/10.1186/s12882-022-02984-4

Karam S, Haidous M, Royal V, Leung N. Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney Int. 2023;103(3):473-84. DOI: https://doi.org/10.1016/j.kint.2022.10.028

Gurung R, Li T. Renal Amyloidosis: Presentation, Diagnosis, and Management. Am J Med. 2022;135:S38-43. DOI: https://doi.org/10.1016/j.amjmed.2022.01.003

Xu J, Wang M, Shen Y, Yan M, Xie W, Wang B, et al. Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study. Cancer Manag Res. 2021;13:1343-56. DOI: https://doi.org/10.2147/CMAR.S287922